Results 141 to 150 of about 24,233 (282)
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló +5 more
wiley +1 more source
Editorial: From Thinker to Doer: Creativity, Innovation, Entrepreneurship, Maker, and Venture Capital. [PDF]
Wu YJ, Yuan CH, Chen MY.
europepmc +1 more source
The impacts of biological invasions
ABSTRACT The Anthropocene is characterised by a continuous human‐mediated reshuffling of the distributions of species globally. Both intentional and unintentional introductions have resulted in numerous species being translocated beyond their native ranges, often leading to their establishment and subsequent spread – a process referred to as biological
Phillip J. Haubrock +42 more
wiley +1 more source
Global venture capital flows and US health care innovation. [PDF]
Ji Y, Kang SY.
europepmc +1 more source
Institutional Entrepreneurship and Work for Enhanced Sustainability at the Base of the Pyramid
ABSTRACT Promoting sustainability at the base of the pyramid (BoP) often falls short of inclusive development due to informal and fragmented institutions, creating institutional voids. Although institutions are critical in BoP settings, there is limited clarity on how institutional mechanisms can address sustainability challenges in low‐income contexts
Nikolas K. Kelling +2 more
wiley +1 more source
The Inflation Reduction Act's Impact Upon Early-Stage Venture Capital Investments. [PDF]
Schulthess DG +4 more
europepmc +1 more source
ABSTRACT Regulators in the banking industry in the Sub‐Saharan Africa (SSA) region are progressively concentrating on corporate innovation and bank social, health and environmental disclosures (BSHED) as crucial corporate governance (CG) structures to improve bank financial performance (BFP).
Douglas A. Adu +3 more
wiley +1 more source

